Next Article in Journal
In Vitro Cytotoxicity of 3,3′,4′,7-Tetrahydroxyflavone Derivatives in Human Osteosarcoma
Previous Article in Journal
Synthesis and Chemical Reactivity of Novel Polyhydroxylated Bis-Chalcones
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medical Sciences Forum
Volume 14
Issue 1
10.3390/ECMC2022-13310
msf-logo
Submit to this Journal
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Desialylation of Blood Plasma Lipoproteins by Exogenous Sialidase †

by
Evgeny Bezsonov
1,2,3,* and
Dmitry Kashirskikh
2
1
Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia
2
Laboratory of Cellular and Molecular Pathology of Cardiovascular System, Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution “Petrovsky National Research Centre of Surgery”, 117418 Moscow, Russia
3
Department of Biology and General Genetics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 105043 Moscow, Russia
*
Author to whom correspondence should be addressed.
†
Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022; Available online: https://ecmc2022.sciforum.net/.
Med. Sci. Forum 2022, 14(1), 107; https://doi.org/10.3390/ECMC2022-13310
Published: 1 November 2022
(This article belongs to the Proceedings of The 8th International Electronic Conference on Medicinal Chemistry)
Versions Notes

Abstract

:
Objective: Sialidases can play an important role in atherosclerosis development due to modification of low-density lipoproteins (LDL). It is known that desialylated LDLs are associated with atherosclerosis development. However, the information about factors leading to desialylation of LDL needs clarifying. The creation of an appropriate model object could help to understand factors related to desialylation of LDL. The aim of this study was to test the possibility to change sialylation of lipoproteins in healthy mice upon an injection of immobilized sialidase. Methods: The control group of C57BL6 mice (n = 48) was treated by a single injection of saline, while the experimental group (n = 48) received Vibrio cholerae sialidase conjugated with mouse IgG. Mice were terminated at fixed periods: before and after a single injection (one to seven days). LDL was isolated from serum by ultracentrifugation. The content of sialic acid was determined according to Warren’s method. Lipids of serum were measured by commercial kits. Results: A significant decrease in LDL sialic acid by 30% was detected up to five days after the sialidase injection. Additionally, serum levels of triglycerides, total cholesterol, and HDL-cholesterol in experimental mice did not differ compared with wild-type control mice. Conclusions: A new approach to study the role of sialidase as a proatherogenic factor in vivo was established.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ECMC2022-13310/s1.

Author Contributions

Conceptualization, D.K. and E.B.; methodology, D.K.; validation, D.K. and E.B.; formal analysis, D.K.; investigation, D.K.; resources, D.K.; data curation, D.K.; writing—original draft preparation, E.B.; writing—review and editing, E.B.; visualization, D.K.; supervision, D.K.; project administration, D.K.; funding acquisition, D.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Russian Science Foundation grant number 20-15-00264.

Conflicts of Interest

The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Bezsonov, E.; Kashirskikh, D. Desialylation of Blood Plasma Lipoproteins by Exogenous Sialidase. Med. Sci. Forum 2022, 14, 107. https://doi.org/10.3390/ECMC2022-13310

AMA Style

Bezsonov E, Kashirskikh D. Desialylation of Blood Plasma Lipoproteins by Exogenous Sialidase. Medical Sciences Forum. 2022; 14(1):107. https://doi.org/10.3390/ECMC2022-13310

Chicago/Turabian Style

Bezsonov, Evgeny, and Dmitry Kashirskikh. 2022. "Desialylation of Blood Plasma Lipoproteins by Exogenous Sialidase" Medical Sciences Forum 14, no. 1: 107. https://doi.org/10.3390/ECMC2022-13310

APA Style

Bezsonov, E., & Kashirskikh, D. (2022). Desialylation of Blood Plasma Lipoproteins by Exogenous Sialidase. Medical Sciences Forum, 14(1), 107. https://doi.org/10.3390/ECMC2022-13310

Article Metrics

Back to TopTop